Evidence map›Paper›PMID 31805379›Full record

ArticleMetabolic engineering2020

Engineering of Chinese hamster ovary cell lipid metabolism results in an expanded ER and enhanced recombinant biotherapeutic protein production.

James D Budge, Tanya J Knight, Jane Povey, Joanne Roobol, Ian R Brown, Gurdeep Singh, Andrew Dean, Sarah Turner, Colin M Jaques, Robert J Young and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Metabolic engineering, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Cell Engineering for Increasing Production of Recombinant Proteins in Mammalian Cells.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026
    Review
  5. Deciphering the determinants of recombinant protein expression across the human secretome.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

James D BudgeIndustrial Biotechnology Centre, School of Biosciences, University of Kent, Canterbury, Kent, CT2 7NJ, UK.
Tanya J KnightIndustrial Biotechnology Centre, School of Biosciences, University of Kent, Canterbury, Kent, CT2 7NJ, UK.
Jane PoveyIndustrial Biotechnology Centre, School of Biosciences, University of Kent, Canterbury, Kent, CT2 7NJ, UK.
Joanne RoobolIndustrial Biotechnology Centre, School of Biosciences, University of Kent, Canterbury, Kent, CT2 7NJ, UK.
Ian R BrownIndustrial Biotechnology Centre, School of Biosciences, University of Kent, Canterbury, Kent, CT2 7NJ, UK.
Gurdeep SinghIndustrial Biotechnology Centre, School of Biosciences, University of Kent, Canterbury, Kent, CT2 7NJ, UK.
Andrew DeanLonza Biologics, 228 Bath Road, Slough, SL1 4DX, UK.
Sarah TurnerLonza Biologics, 228 Bath Road, Slough, SL1 4DX, UK.
Colin M JaquesLonza Biologics, 228 Bath Road, Slough, SL1 4DX, UK.
Robert J YoungCell Engineering Group, Lonza Biologics, Granta Park, Cambridge, CB21 6GS, UK.
Andrew J RacherLonza Biologics, 228 Bath Road, Slough, SL1 4DX, UK.
C Mark SmalesIndustrial Biotechnology Centre, School of Biosciences, University of Kent, Canterbury, Kent, CT2 7NJ, UK. Electronic address: c.m.smales@kent.ac.uk.
University of Kent · GBLonza (United Kingdom) · GB

Funding

Biotechnology and Biological Sciences Research Council BB/N023501/1
6 · The paper itself

Abstract

Chinese hamster ovary (CHO) cell expression systems have been exquisitely developed for the production of recombinant biotherapeutics (e.g. standard monoclonal antibodies, mAbs) and are able to generate efficacious, multi-domain proteins with human-like post translational modifications at high concentration with appropriate product quality attributes. However, there remains a need for development of new CHO cell expression systems able to produce more challenging secretory recombinant biotherapeutics at higher yield with improved product quality attributes. Amazingly, the engineering of lipid metabolism to enhance such properties has not been investigated even though the biosynthesis of recombinant proteins is at least partially controlled by cellular processes that are highly dependent on lipid metabolism. Here we show that the global transcriptional activator of genes involved in lipid biosynthesis, sterol regulatory element binding factor 1 (SREBF1), and stearoyl CoA desaturase 1 (SCD1), an enzyme which catalyzes the conversion of saturated fatty acids into monounsaturated fatty acids, can be overexpressed in CHO cells to different degrees. The amount of overexpression obtained of each of these lipid metabolism modifying (LMM) genes was related to the subsequent phenotypes observed. Expression of a number of model secretory biopharmaceuticals was enhanced between 1.5-9 fold in either SREBF1 or SCD1 engineered CHO host cells as assessed under batch and fed-batch culture. The SCD1 overexpressing polyclonal pool consistently showed increased concentration of a range of products. For the SREBF1 engineered cells, the level of SREBF1 expression that gave the greatest enhancement in yield was dependent upon the model protein tested. Overexpression of both SCD1 and SREBF1 modified the lipid profile of CHO cells and the cellular structure. Mechanistically, overexpression of SCD1 and SREBF1 resulted in an expanded endoplasmic reticulum (ER) that was dependent upon the level of LMM overexpression. We conclude that manipulation of lipid metabolism in CHO cells via genetic engineering is an exciting new approach to enhance the ability of CHO cells to produce a range of different types of secretory recombinant protein products via modulation of the cellular lipid profile and expansion of the ER.

Indexed as

Batch Cell Culture TechniquesEndoplasmic ReticulumMetabolic EngineeringAnimalsBiological ProductsCHO CellsCricetulusLipid MetabolismRecombinant ProteinsStearoyl-CoA DesaturaseSterol Regulatory Element Binding Protein 1Biological ProductsRecombinant ProteinsStearoyl-CoA DesaturaseSterol Regulatory Element Binding Protein 1Cell line engineeringChinese hamster ovary (CHO) cellsDifficult to express recombinant proteinsER expansionLipid metabolism

Identifiers

PMID31805379
PMCPMC6975165
OpenAlexW2990793476

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.